Cross Country Healthcare Reports Significant Q4 Loss Driven by $77.9M Goodwill Impairment and Weak Guidance

summarizeSummary

Cross Country Healthcare reported a substantial net loss for Q4 and full year 2025, primarily due to a $77.9 million goodwill impairment charge following the termination of a merger agreement and a decline in market capitalization. The company also provided weak Q1 2026 guidance.

check_boxKey Events

• Major Impairment Charge

  Reported a $77.9 million goodwill and trade name impairment charge and a $29.6 million valuation allowance against deferred tax assets, leading to a net loss of $82.9 million for Q4 2025.

• Weak Financial Performance

  Q4 2025 revenue decreased 24% year-over-year, and Adjusted EBITDA declined 56% year-over-year, with full-year results also showing significant declines.

• Negative Q1 2026 Outlook

  Provided guidance for Q1 2026 projecting continued year-over-year declines in revenue and Adjusted EBITDA, along with a net loss.

• Merger Termination Impact

  The goodwill impairment was directly linked to the decline in market capitalization following the termination of the Aya Merger Agreement, highlighting the financial repercussions of the failed deal.

auto_awesomeAnalysis

The significant net loss and diluted EPS miss for the fourth quarter and full year 2025 are primarily attributable to a substantial $77.9 million goodwill and trade name impairment charge, coupled with a $29.6 million valuation allowance against deferred tax assets. This impairment was directly triggered by the decline in the company's equity market capitalization following the termination of the Aya Merger Agreement, indicating a significant re-evaluation of the company's asset values and future prospects. While the company maintains a strong cash position and repurchased shares, the overall financial performance and the weak outlook for Q1 2026 suggest ongoing operational challenges and a difficult market backdrop, particularly in travel staffing. Investors should monitor the company's ability to execute on its stated goal of improving revenue run-rate and profit margins throughout 2026.